

Biosynthesis of cannabigerol and cannabigerolic acid: the gateways to further cannabinoid production

Lewis J. Kearsley¹, Cunyu Yan², Nicole Prandi^{1,4}, Helen S. Toogood¹, Eriko Takano^{id 1,2,3}, and Nigel S. Scrutton^{id 1,2,3,*}

¹Manchester Institute of Biotechnology and School of Chemistry, University of Manchester, Manchester M1 7DN, UK

²BBSRC/EPSC Synthetic Biology Research Centre SYNBIOCHEM, University of Manchester, Manchester M1 7DN, UK

³EPSC/BBSRC Future Biomanufacturing Research Hub, The University of Manchester, Manchester M1 7DN, UK

⁴Current address: Colorifix Ltd, Norwich Research Park Innovation Centre, Colney Ln, Norwich NR4 7GJ, United Kingdom.


*Corresponding author: E-mail: nigel.scrutton@manchester.ac.uk

Abstract

Cannabinoids are a therapeutically valuable class of secondary metabolites with a vast number of substituents. The native cannabinoid biosynthetic pathway of *Cannabis sativa* generates cannabigerolic acid (CBGA), the common substrate to multiple cannabinoid synthases. The bioactive decarboxylated analog of this compound, cannabigerol (CBG), represents an alternate gateway into the cannabinoid space as a substrate either to non-canonical cannabinoid synthase homologs or to synthetic chemical reactions. Herein, we describe the identification and repurposing of aromatic prenyltransferase (AtaPT), which when coupled with native enzymes of *C. sativa* can form an *Escherichia coli* production system for CBGA in cell lysates and CBG in whole cells. Engineering of AtaPT, guided by structural analysis, was performed to enhance its kinetics toward CBGA production for subsequent use in a proof-of-concept lysate system. For the first time, we show a synthetic biology platform for CBG biosynthesis in *E. coli* cells by employing AtaPT under an optimized microbial system. Our results have therefore set the foundation for sustainable production of well-researched and rarer cannabinoids in an *E. coli* chassis.

Key words: Cannabigerol; cannabigerolic acid; synthetic biology; *Escherichia coli*; aromatic prenyltransferase

Graphical Abstract



1. Introduction

Cannabinoids are a unique class of secondary metabolites that are found exclusively within the plant species *Cannabis sativa* (1). Over 100 compounds have been identified, and a number have been investigated for their therapeutic potential (2). The two most prominent targets are tetrahydrocannabinol (THC) and cannabidiol (CBD) due to their abundance in the plant and well-established therapeutic uses. They have been proven to be effective in treating the side effects associated with chemotherapy, anorexia

in HIV patients and reducing spasticity in multiple sclerosis (3, 4).

There is now an interest in investigating the potential therapeutic use(s) of less abundant cannabinoids. One example is cannabigerolic acid (CBGA), the common intermediate to cannabinoid production pathways (5), including THC and CBD. The decarboxylated analog cannabigerol (CBG) also represents an entry point to the synthesis of an array of cannabinoids (6). It has proven efficacy in the treatment of glioblastoma brain tumors

Submitted: 9 January 2023; Received (in revised form): 10 May 2023; Accepted: 24 May 2023

© The Author(s) 2023. Published by Oxford University Press.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

(7), reducing neuroinflammation in neurodegenerative diseases (8) and as a treatment for chemotherapy side effects without psychoactive side effects (9).

There is a growing interest to displace existing routes to a variety of natural products currently extracted from plants (or chemically synthesized) with sustainable and renewable biological routes. This is because *C. sativa* extracts contain only small quantities of the target compounds, which are heavily contaminated with a variety of other organic compounds. Therefore, synthetic biology routes to microbially sourced cannabinoids are an attractive proposition. The *C. sativa* metabolic pathway from central metabolites hexanoyl-CoA and malonyl-CoA to cannabinoids has been well characterized (Figure 1 (2, 3, 10–13)). Synthetic biology routes to THC and CBD in *Saccharomyces cerevisiae* were successful by the incorporation of native *C. sativa* pathway enzymes (12). An alternative cell-free system was designed that produced ~0.5 g/l CBGA or cannabigerovarinic acid from low-cost materials, which was nearly two orders of magnitude higher than yeast-based production (14, 15).

We previously demonstrated the production of THC/CBD precursors olivetolic acid (OA) and by-product olivetol in *Escherichia coli* by expressing the native tetraketide synthase (TKS) and OA cyclase (OAC) from *C. sativa* (10, 11, 13) (Figure 1). The addition of a

promiscuous aromatic prenyltransferase (APT; (16)) to this pathway could enable biosynthetic routes to CBGA and CBG, respectively (Figure 1). This enzyme transfers the prenyl donor geranyl pyrophosphate (GPP) to olivetol and OA, with the former originating from the methylerythritol phosphate pathway of *C. sativa* (17). As the *C. sativa* APTs CsPT1 and four are membrane-embedded, a bacterial homolog would be preferable to maximize the solubility in *E. coli*.

In this study, we describe the proof-of-principle demonstration of a synthetic biology pathway for CBGA and CBG production in *E. coli*, based on the earlier route to OA and olivetol (11). We identified an aromatic prenyltransferase homolog from *Aspergillus terreus* (AtaPT) (18) that uses GPP to prenylate OA and olivetol to CBGA and CBG, respectively. To optimize cannabinoid production, AtaPT variants were generated to improve substrate binding. We performed both *in vitro* and *in vivo* studies to optimize CBGA and/or CBG production, including upregulating GPP precursor availability (19). Overall, this proof-of-principle study demonstrates the potential of microbial routes toward functionalized cannabinoids.

2. Materials and Methods

2.1 Plasmids and strains

All chemicals and reagents were commercially sourced and were of analytical grade or better. The genes encoding the aromatic prenyltransferases from *C. sativa* CsPT1 and *Aspergillus terreus*, AtaPT (UniProtKB: A0A455ZIK6 and A0A1B0UHJ4) were synthesized by GeneArt (Thermo Fisher), incorporating codon optimization for improved expression in *E. coli*. Plasmid pBbB2c-OA not only is based on the pBbB2c-TKS-OAC plasmid described previously for the production of OA (11) but also contains the gene encoding GPP synthase (GPPS). The mevalonate (MVA) pathway construct (pMVA) was constructed as described previously (19). Plasmid pMVA is a derivative of the limonene-producing construct pBEI6410 (20) but lacks the genes encoding GPPS and limonene synthase (21). It contains operons for the upper and lower MVA pathway (MevT and MevB), controlled by the *lacUV5* and *trc* promoters, respectively (Supplementary Figure S1). Plasmid pBbB2a-GPPS-LinS contains the downstream enzymes catalyzing linalool biosynthesis from isopentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP) (21). A list of all plasmids used in this study is shown in Table 1.

Coding sequences for assembly of the OA-producing construct (pBbB2c-OA) were codon optimized for the expression in *E. coli* and ordered from Twist Bioscience. The parts were amplified via PCR using Phusion Hotstart Flex New England Biolabs (NEB) and assembled on a pBbB2c backbone using the ligase cyclic reaction method as described previously (22). The correct assembly was confirmed via restriction analysis and DNA sequencing (GATC Biotech).

Recombinant protein expression was performed using *E. coli* strains ArcticExpress (DE3) (Agilent Technologies), BL21 (DE3) and NEB5 α (New England Biolabs). Olivetol and CBG production were also tested using the *E. coli* DH5 α Δ *fabF* variant (23), designed to reduce malonyl-CoA consumption in fatty acid biosynthesis by knocking out the 3-oxoacyl-(acyl carrier protein) synthase II (*fabF*) gene.

2.2 Subcloning and mutagenesis

All oligonucleotides used for cloning and mutagenesis are listed in Supplementary Tables S1 and S2. Both the CsPT1 and AtaPT genes were subcloned into pETM11 by restriction cloning at the *Xho*I and *Nco*I sites, which incorporated an N-terminal His₆-tag. The AtaPT




Figure 1. Enzymatic pathways to CBGA and CBG from starting substrates hexanoyl-CoA, malonyl-CoA and GPP. (A) In green is the route to CBGA using TKS, OAC and AtaPT. In purple is the route to CBG using the genes TKS and AtaPT via the ‘by-product’ olivetol. (B) MVA pathway from 2 acetyl-CoA molecules to IPP and DMAPP encoded on the pMVA NR2 plasmid (Supplementary Information Figure S1). Enzymes: GPPS = geranyl diphosphate synthase and OAC = olivetolic acid cyclase. Chemicals: HTAL = hexanoyl triacetic acid lactone and PDAL = pentyldiacetic lactone.

Table 1. Plasmids used in this study

Plasmid	Description ¹	Source/Ref
pBbB2c-OA	pBbB2c; <i>Cam</i> ^R ; <i>P</i> _{tet} -TKS-OAC-GPPS	Dr Nicole Prandi ²
pMVA	p15A, <i>Kan</i> ^R , <i>P</i> _{lacUV5} - <i>MevT</i> - <i>TrrmBT1</i> -TT7TE, <i>P</i> _{trc} - <i>MevB</i> - <i>TrrmBT1</i> -TT7TE	(19, 21)
pET-M11-AtaPT ³	pET-M11; <i>Kan</i> ^R ; <i>P</i> _{T7} -His ₆ -AtaPT	Gene art
pBbB2c-CBGA	pBbB2c; <i>Cam</i> ^R ; <i>P</i> _{tet} -TKS-OAC-AtaPT-GPPS	This study
pBbB2c-CBG	pBbB2c; <i>Cam</i> ^R ; <i>P</i> _{tet} -TKS-AtaPT-GPPS	This study
pBbB2c-CBGA	pBbB2c; <i>Cam</i> ^R ; <i>P</i> _{tet} -TKS-OAC- <i>P</i> _{BAD} -AtaPT-GPPS	This study
pBbB2c-CBGA_ <i>P</i> _{BAD} *	pBbB2c; <i>Cam</i> ^R ; <i>P</i> _{tet} -TKS-OAC- <i>P</i> _{BAD} -AtaPT-GPPS	This study
pBbB2c-CBGA_ <i>P</i> _{J23100} *	pBbB2c; <i>Cam</i> ^R ; <i>P</i> _{tet} -TKS-OAC- <i>P</i> _{J23100} -AtaPT-GPPS	This study
pBbB2c-CBGA_ <i>P</i> _{J23105} *	pBbB2c; <i>Cam</i> ^R ; <i>P</i> _{tet} -TKS-OAC- <i>P</i> _{J23105} -AtaPT-GPPS	This study
pBbB2c-CBGA_ <i>P</i> _{J23116} *	pBbB2c; <i>Cam</i> ^R ; <i>P</i> _{tet} -TKS-OAC- <i>P</i> _{J23116} -AtaPT-GPPS	This study
pBbB2c-CBGA_ <i>P</i> _{J23119} *	pBbB2c; <i>Cam</i> ^R ; <i>P</i> _{tet} -TKS-OAC- <i>P</i> _{J23119} -AtaPT-GPPS	This study
pBbB2c-CBGA_ <i>P</i> _{J23150} *	pBbB2c; <i>Cam</i> ^R ; <i>P</i> _{tet} -TKS-OAC- <i>P</i> _{J23150} -AtaPT-GPPS	This study
pBbB1c-CBGA*	pBbB1c; <i>Cam</i> ^R ; <i>P</i> _{trc} -TKS-OAC-AtaPT-GPPS	This study
pBbB1c-CBGA_ <i>P</i> _{trc} *	pBbB1c; <i>Cam</i> ^R ; <i>P</i> _{trc} -TKS-OAC- <i>P</i> _{trc} -AtaPT-GPPS	This study
pBbB1c-CBGA_ <i>P</i> _{lacUV5} *	pBbB1c; <i>Cam</i> ^R ; <i>P</i> _{trc} -TKS-OAC- <i>P</i> _{lacUV5} -AtaPT-GPPS	This study
pBbB5c-CBGA*	pBbB1c; <i>Cam</i> ^R ; <i>P</i> _{lacUV5} -TKS-OAC-AtaPT-GPPS	This study
pBbB5c-CBGA_ <i>P</i> _{trc} *	pBbB1c; <i>Cam</i> ^R ; <i>P</i> _{lacUV5} -TKS-OAC- <i>P</i> _{trc} -AtaPT-GPPS	This study
pBbB5c-CBGA_ <i>P</i> _{lacUV5} *	pBbB1c; <i>Cam</i> ^R ; <i>P</i> _{lacUV5} -TKS-OAC- <i>P</i> _{lacUV5} -AtaPT-GPPS	This study

¹Plasmid backbone, antibiotic marker and promoter-operon.

²University of Manchester, UK.

³Additional clones with mutations in AtaPT are described in the Supplementary Results S3 section. Genes: OAC = olivetolic acid cyclase; TKS = tetraketide synthase. Clones indicated with an asterisk are discussed in the Supplementary Results S3 section. The Genbank accession numbers for each plasmid generated in this study are in the Supporting Information document.

variants E91A, E91D and E91Q were generated using the Q5 site-directed mutagenesis kit (New England Biolabs), according to the manufacturer's instructions.

The following modified plasmids were generated in this study: The OA plasmid pBbB2c-OA was modified to replace the OAC gene with AtaPT. This plasmid was modified to insert the variant AtaPT_{E91Q} gene to generate pBbB2c-CBGA (pBbB2c-TKS-OAC-AtaPT_{E91Q}-GPPS). The GPPS precursor pathway plasmid pMVA (21) was modified to incorporate a constitutive J23116 promoter in place of the existing *trc* promoter upstream of the MVA kinase (*ScMK*) gene (Supplementary Figure S1). The correct assembly of each construct was confirmed by gene sequencing (Eurofins Genomics). Further details of the cloning and assembly of each construct are found in Supplementary Method S1.

2.3 Enzyme kinetics and biotransformations of purified proteins

The expression and purification of individual enzymes TKS and OAC were performed in *E. coli* (DE3) ArcticExpress using the protocols described previously (11). Both wild-type (WT) AtaPT and variant AtaPT were expressed in *E. coli* (DE3) ArcticExpress, and details of purification protocol are provided in Supplementary Method S2.

Steady state kinetics of purified WT and variant AtaPT was performed using an endpoint assay. Reaction mixtures (200 µl) were composed of buffer (25 mM Tris pH 8, 150 mM NaCl and 5% glycerol) containing GPP (1 mM), AtaPT (1 µM; 10 µM for WT) and OA (0–10 mM). Each reaction mixture was incubated for 20 min at 25°C. Biotransformations with purified enzymes were performed in a similar manner, except for the reaction volume (250 µl), incubation time (overnight), substrate concentration (10 µM each of hexanoyl-CoA, malonyl-CoA, OA and/or GPP) and enzyme concentrations (10 µM; TKS, OAC and/or WT or variant AtaPT).

Each reaction was stopped by the addition of an equal volume of ethyl acetate. The samples were vortexed to extract the substrate and product into the organic phase and then clarified by centrifugation for 10 min at 17 900 *g*. The organic phase

(150 µl) was removed, dried in a vacuum centrifuge and then resuspended in an equal volume of 50% methanol for quantitative liquid chromatography–mass spectrometry (LC–MS) analysis. All assays were performed in triplicate, with the errors representing one standard deviation of the data.

2.4 In vitro biotransformations for CBGA production

Escherichia coli strain BL21 (DE3) was co-transformed with plasmids pBbB2c-OA and pETM11-AtaPT_{E91Q} according to the manufacturer's protocol. Biological triplicate cultures (50 ml) were cultivated in Luria-Bertani media (LB: 10 g/l tryptone, 5 g/l yeast extract and 10 g/l NaCl) containing 40 µg/ml kanamycin and 35 µg/ml chloramphenicol. The cultures were incubated at 37°C until an optical density at 600 nm of 0.6–0.8 was reached. The incubation temperature was reduced to 16°C, and recombinant protein expression was induced with 0.1 mM isopropyl-β-D-thiogalactopyranoside (IPTG) and 200 nM anhydrotetracycline (aTet) for plasmids pETM11-AtaPT_{E91Q} and pBbB2c-OA, respectively. Cultures were incubated overnight at 16°C and then harvested by centrifugation, and cell lysates were generated according to the method in Supplementary Method S3.

Reaction mixtures (~1 ml) were composed of 1 ml of lysate containing 10 µM each of hexanoyl-CoA, malonyl-CoA and GPP. Mixtures were incubated overnight at 25°C followed by the addition of 900 µl of ethyl acetate to 900 µl of the reaction mixture. Product(s) were extracted into the organic layer by vortexing, and emulsion clarification was performed by centrifugation for 10 min at 17 900 *g*. The organic layer (750 µl) was dried using a vacuum centrifuge and resuspended in 150 µl of 50% methanol for MS analysis. Error bars represent one standard deviation of the data from biological triplicate reactions.

2.5 In vivo biotransformations

pMVA NR2 in vivo testing. The functional expression of pMVA_NR2 to produce GPP precursors IPP and DMAPP was tested

by co-expressing it with plasmid pBbB2a-GPPS-LinS containing the remaining biosynthetic genes to the monoterpenoid linalool (21). These plasmids were co-transformed into *E. coli* NEB5 α , and individual colonies were inoculated into 3 ml of phosphate-buffered Terrific broth (TB) media (Formedium; 12 g/l tryptone, 24 g/l yeast extract, 9.4 g/l KH₂PO₄ and 2.2 g/l K₂HPO₄) containing 40 μ g/ml kanamycin and 100 μ g/ml ampicillin. The cultures were grown at 37°C until growth was visible and then induced with 50 μ M IPTG and 200 nM aTet for plasmids pMVA_NR2 and pBbB2a-GPPS-LinS, respectively. Cultures were incubated at 30°C for 72 h, and linalool was extracted by vortexing with 1 ml of ethyl acetate. The emulsion was clarified by centrifugation for 10 min at 17900 g, and the organic solvent was dried with anhydrous MgSO₄. Linalool content was quantified by Gas Chromatography Mass Spectrometry (GCMS), with the error bars representing the standard deviation of data from five biological triplicates.

In vivo production of cannabinoids. The constructs pBbB2c-CBG or pBbB2c-CBGA were co-transformed with pMVA_NR2 into *E. coli* NEB5 α and the *E. coli* DH5 α Δ *fabF* variant using manufacturer-specified chemical transformation and electroporation protocols, respectively. Electroporation was performed using a MicroPulser (Bio-Rad) with the bacterial protocol *E. coli* 2 (0.2 cm cuvette, 200 Ω current, 25 μ F capacitance and 2.5 kV). Single colonies from the transformations (biological triplicates) were inoculated into phosphate-buffered TB media containing 0.4% glycerol, 40 μ g/ml kanamycin and 35 μ g/ml chloramphenicol. Cultures (3 and 25 ml for olivetol and CBG production, respectively) were cultivated at 37°C for 8 h and then induced with 50 μ M IPTG and 200 nM aTet. The cultures were incubated for 72 h at 20°C, 25°C and 30°C, where specified. Aliquots (2 ml) of each culture were extracted with 2 ml of ethyl acetate, as described earlier. The organic layer (1.5 ml) was dried using a vacuum centrifuge and resuspended in 150 μ l of 50% methanol for LC-MS analysis.

For monitoring the distribution of olivetol and CBG between culture medium and cells, the same protocol as earlier was used with four biological replicate cultures (25 ml) cultivated after induction at 30°C. Culture samples (25 ml) were centrifuged at 8000 g, and 2 ml of the clarified supernatant was extracted with ethyl acetate and processed for LC-MS analysis as earlier. The pelleted cells were resuspended in 2.5 ml of lysis buffer and lysed as described in Supplementary Method S3. The lysate (2 ml) was extracted with an equal volume of ethyl acetate and processed for LC-MS analysis as described earlier.

2.6 Analytical procedures

The product profile of AtaPT was identified and quantified using LC-MS using a 1290 Infinity II UHPLC coupled to a 6560 Ion Mobility Q-TOF (Agilent). The quantitative analysis of product formation was performed by using a Xevo TQ-S triple quadrupole tandem mass spectrometer (Waters MS Technologies) connected to an Acquity UPLC system (H-Class; Waters). Olivetol and CBG separation was performed by LCMS on a BEH C8 column (1.7 μ m, 2.1 \times 50 mm, Waters). Linalool quantitation was performed by GCMS using an Agilent Technologies 7890B GC equipped with a 5977A MSD detector. Product concentrations were determined by comparing peak areas to a standard curve generated from authentic standards run under identical conditions. Further details of the running conditions for compound identification and quantitation are found in Supplementary Methods S4.

3. Results and Discussion

3.1 Identification and engineering of prenyltransferase homolog AtaPT

We sought to identify potential candidates of non-membrane-bound soluble aromatic prenyltransferases as the expression of the *C. sativa* prenyltransferase CsPT1 did not yield soluble protein (Supplementary Results S1 and Figure S2). To identify potential candidates, a SWISS-MODEL (24–29) of CsPT1 (GenBank: BK010678.1) was generated, based on the crystal structure of the membrane-embedded prenyltransferase (UBiA) from *Archaeoglobus fulgidus* (30) (Protein Data Bank: 4TQ3; <https://www.rcsb.org/>), to identify the likely sequence regions encoding membrane anchors (Supplementary Figure S3). The related UBiA superfamily member *C. sativa* homolog CsPT4 was predicted to contain eight transmembrane helices (12), which may account why these enzymes are difficult to solubly express in *E. coli*. To bypass this problem, alternative enzymes that do not contain the transmembrane domains were sought. The aromatic prenyltransferase from *Aspergillus terreus* (AtaPT) was identified, which was previously shown in the literature to express in soluble form in *E. coli* and has exceptional promiscuity toward diverse aromatic acceptors and prenyl donors (18). The crystal structure of AtaPT is known (18), which confirms the absence of the transmembrane helices seen with UBiA homologs.

After successful expression in *E. coli* (Supplementary Figure S4), biotransformations of purified AtaPT showed that CBGA was produced with four major side products (Figure 2a; Supplementary Figure S5). These by-products may be isomers of CBGA, where the highly promiscuous AtaPT has prenylated OA at multiple positions on its ring. Prior studies showed that the AtaPT product profile distribution could be altered by mutating residue Glu 91 to alanine,




Figure 2. *In vitro* activity of WT and variants of AtaPT. (A) Product profiles of purified WT AtaPT and variants E91A, E91D and E91Q AtaPT variants from reactions with OA and GPP. Reaction mixtures (250 μ l) were composed of 10 μ M each of OA and GPP and 10 μ M of AtaPT in buffer (25 mM Tris pH 8, 150 mM NaCl and 5% glycerol). After incubating at 25°C for 20 min, the products were extracted with ethyl acetate and dried. Each sample was redissolved in 50% methanol and analyzed using a 6560 Ion Mobility Q-TOF LC-MS. The full spectra are shown in Supplementary Figure S5. The peaks representing CBGA are highlighted as a vertical shaded bar. (B) *In vitro* screening of purified WT AtaPT and variants for CBG production in the presence or absence of OAC. Reactions were performed as described in (A). Error bars represent one standard deviation of biological triplicates. (C) Lysate assay of *E. coli* BL21 (DE3) expressing pBbB2c-OA \pm pETM11-AtaPT_{E91Q}. Reaction mixtures were composed of 1 ml of cell lysate with 10 μ M each of hexanoyl-CoA, malonyl-CoA and GPP. Samples were extracted and analyzed as earlier. 1 nM CBGA and CBG are equivalent to 0.361 and 0.316 μ g/ml, respectively.

Table 2. Apparent Michaelis-Menten kinetics of wild-type AtaPT and variants

AtaPT Variant	Apparent K_m (μM)	Apparent k_{cat} (min^{-1})
Wild type	1083 ± 126	0.0088 ± 0.0003
E91A	332 ± 96	0.0149 ± 0.0013
E91D	266 ± 44	0.0417 ± 0.0019
E91Q	94 ± 32	0.131 ± 0.0094

Apparent Michaelis-Menten plots can be found in [Supplementary Figure S6](#). These kinetic constants are only approximations as the low steady state activity of the enzymes required relatively high enzyme concentrations to be used (31).

aspartate or glutamine without adversely affecting the overall catalytic activity (18). This is so because residue 91 appears to discriminate between the orientation of the aromatic substrates as it enters the active site. We presumed that a similar discrimination between substrate orientations could be generated by making the equivalent Glu91 variants in AtaPT. We found that both AtaPT_{E91D} and AtaPT_{E91Q} produced primarily CBGA with a reduction in by-product formation (Figure 2a), while AtaPT_{E91A} showed a WT-like product profile. There appears to be an interplay between changes in the residue R-group charge and/or steric bulk, which affects the prioritization of OA binding in an orientation favoring CBGA production.

3.2 Kinetics of WT and variant AtaPT

The apparent kinetic constants of purified WT and AtaPT variants with OA were determined to further investigate the effect of the mutations (Table 2; Supplementary Figure S6). True Michaelis-Menten kinetics constants were not determined due to the low specific activity of each enzyme (i.e. the condition that $[E] \ll [S]$ was not possible) (31). Variants AtaPT_{E91Q} and AtaPT_{E91A} showed an increase in OA binding specificity ($94 \pm 32 \mu\text{M}$ and $332 \pm 96 \mu\text{M}$, respectively; versus WT $1083 \pm 126 \mu\text{M}$). As these two variants display quite different product profiles, the common increase in OA binding is likely due to different factors, such as changes in the residue charge and/or the removal of steric bulk to allow OA to bind more favorably.

The apparent k_{cat} of WT and AtaPT_{E91A} showed similar turnover numbers (Table 2), while AtaPT_{E91Q} showed an almost 15-fold increase in apparent k_{cat} ($0.131 \pm 0.0094 \text{ min}^{-1}$). Additional variants were generated based on studies with the homologous aromatic prenyltransferase NphB from *Streptomyces* sp. strain CL190 (32), but they did not improve the activity and/or specificity of AtaPT (Supplementary Results S2 and Figures S7 and S8). Therefore, AtaPT_{E91Q} was taken forward for *in vivo* CBGA production due to its high specificity and lower side product formation.

3.3 *In vitro* multienzyme production of CBG and CBGA

Olivetol is the decarboxylated analog of OA generated by the action of TKS alone in the absence of OAC (Figure 1). Using olivetol in place of OA, AtaPT could potentially generate CBG (Figure 1). This may be an alternate entry point into the lucrative, therapeutically active, decarboxylated cannabinoid chemical space. Biotransformations of purified TKS with WT and variant AtaPT all generated CBG (Figure 2b), with WT AtaPT and AtaPT_{E91A} showing the highest titers ($180.6 \pm 19.0 \text{ nM}$ and $173.7 \pm 23.0 \text{ nM}$, respectively). As expected, the addition of enzyme OAC showed that both CBGA and CBG were produced, with similar titers of $53.7 \pm 11.8 \text{ nM}$ and $65.3 \pm 4.3 \text{ nM}$, respectively (Figure 2b). This decrease in CBG production in the presence of enzyme OAC is likely due to carbon

being split between the two biosynthetic routes (dual products). Surprisingly, there are lower titers of CBG with the AtaPT_{E91Q}/TKS construct ($22.1 \pm 3.9 \text{ nM}$) compared to the same construct with OAC being present ($65.3 \pm 4.3 \text{ nM}$). This may be due to the general observation that the addition of extra genes to an operon can lead to changes in the level of expression of the other genes already present. Therefore, both WT and AtaPT_{E91A} were taken forward to investigate *in vivo* CBG production studies.

In the next stage, *in vitro* multienzyme biotransformations for CBGA production were performed using *E. coli* cell lysates of co-expressed TKS, OAC and AtaPT_{E91Q} as the enzyme source (Figure 2c; OAC-AtaPT route in Figure 1). Both the OA precursor and CBGA were generated ($163. \pm 1.8 \text{ nM}$ and $25.8 \pm 2.5 \text{ nM}$, respectively), showing the active expression of each enzyme. The accumulation of OA suggests that further optimization is needed to upregulate AtaPT_{E91Q} expression and/or activity to shift the equilibrium toward CBGA production. This proof-of-principle lysate system shows the potential of using TKS, OAC and AtaPT_{E91Q} in a more cost-effective *in vivo* microbial CBGA production process, which will eliminate the need for supplying costly and unstable coenzyme A derivatives.

3.4 *In vivo* biotransformations in *E. coli* for cannabinoid production

In vivo biotransformations were performed in *E. coli* expressing TKS, OAC and AtaPT_{E91Q} (pBb2c-CBGA) to generate CBGA (and CBG; Supplementary Results S3). The only cannabinoid product detected was OA ($5\text{--}10 \mu\text{g/ml}$; Supplementary Figure S9), so a variety of approaches were used to identify and overcome bottlenecks in the system and perform optimization studies to allow metabolic flux through to CBGA (or CBG). These approaches were based on (i) incorporating the gene GPPS to increase substrate GPP titers for AtaPT activity (Supplementary Results S3 and Figure S9a), (ii) generating a library of twelve genetic circuits with a selection of inducible (33) and constitutive (34) promoters positioned at different points throughout the pathway (Supplementary Figure S9a and b), (iii) increasing GPP supply by incorporating a heterologous MVA pathway (Supplementary Results S4 and Figure S10) and (iv) upregulating intracellular malonyl-CoA levels by using the *E. coli* strain DH5 α $\Delta fabF$ knock-out (Supplementary Results S5 and Figure S10).

The culmination of these studies led to a redesign of biotransformations for CBG and CBGA production by incorporating the gene for GPPS, co-expressing the MVA pathway on a second plasmid (pMVA) and switching to the *E. coli* strain DH5 α $\Delta fabF$. This led to the production of low levels of CBG ($4.3 \pm 2.8 \mu\text{g/l}$ and $0.1 \pm 0.01 \mu\text{g/l}$, respectively; Figure 3a) using the pBb-CBG-GPPS construct with a WT AtaPT and E91A variant, respectively. In contrast, when using the pBb2c-CBGA plasmid, a four-fold increase in OA production was seen (Supplementary Table S3), but no CBGA was detected.

This is the first time that CBG has been produced in a bacterial whole cell system. Unlike the lysate production system, higher titers were seen with WT AtaPT instead of the E91A variant. This may be due to different recombinant protein expression conditions between the *in vitro* and *in vivo* assays. Almost all the CBG was found to be residing in the culture supernatant, with only 11% within the cells (Figure 3a). Higher levels of olivetol were also detected with WT AtaPT, with $84.6 \pm 12.2 \mu\text{g/l}$ found in the supernatant and $30.2 \pm 4.1 \mu\text{g/l}$ in the lysate (Figure 3b). This suggests that there is a secretion system in *E. coli* capable of exporting some cannabinoids.




Figure 3. Olivetol and CBG production from cells or cell lysate expressing the pBb2c-CBG plasmid. Inset: Schematic of genes used in CBG producing constructs. (A) CBG production and localization within the cell or culture supernatant in whole cell biotransformations of constructs containing AtaPT WT and E91A variant. CBG concentration in lysed cells is normalized to the total volume of fermentation. (B) Olivetol localization within the cell or culture supernatant in whole cell biotransformations. Olivetol concentration in lysed cells is normalized to the total volume of fermentation. (C) Production of CBG and olivetol in whole cell biotransformations at different post-induction temperatures. In each part, cultures (25 ml) in TB media containing 0.4% glycerol were grown at 37°C for 8 h then induced and incubated at 30°C for 72 h.

The highest titer of CBG ($32.9 \pm 31.5 \mu\text{g/l}$) was obtained, albeit with high variability, after the post-induction temperature was maintained at 25°C (Figure 3c). High variability in biological replicates (individual colonies) may arise from different levels of plasmid incorporation and/or accumulation of mutation/recombination events, impacting the function of the incorporated pathway. Olivetol was also present at over double the titers, suggesting that GPP supply and/or AtaPT expression/activity is still a bottleneck in this system. While these titers are low, this proof-of-principle demonstration of *in vivo* bacterial cannabinoid production shows the potential of this ‘natural’ biological route.

Despite the demonstration of cannabinoid biosynthesis in yeast, there is still a desire to establish a production platform in an *E. coli* chassis due to its preference for industrial application owing to its 3- to 4-fold faster growth rate than *S. cerevisiae*. Alongside this, a well-characterized genome and established genetic toolbox would allow an *E. coli* system to diverge from the native enzymes of *C. sativa*, which the current *S. cerevisiae* platform relies on. This enables the exploration of homologous enzymes and novel routes to rarer cannabinoids, such as those derived from CBG.

4. Conclusion

This study has demonstrated a proof-of-principle demonstration of complete *in vivo* bacterial CBG production. Previous studies into cannabinoid production in an *E. coli* host only progressed as far as demonstrating OA production in a whole cell system (11). Other approaches include the construction of an *E. coli* prenylation system into which OA is fed to produce CBGA (35) or utilizing a cell-free system for cannabinoid production (14). Here, the use of a non-native prenyltransferase coupled with two substrate upregulation (GPP and malonyl-CoA) led to the development of a fully *in vivo* system for CBG production in *E. coli*. Further studies are required to increase intermediate and final product titers to commercially relevant g/l quantities.

Our construction of a CBG producing strain of *E. coli* demonstrates that by coupling enzymes of native biosynthesis pathways with homologs that show promiscuity toward their substrate, novel routes to therapeutically valuable compounds can be constructed. Here, we employed the native enzymes of *C. sativa* coupled with a promiscuous aromatic prenyltransferase to open two biosynthetic gateways into the cannabinoid chemical space,

via the intermediates CBGA and CBG. Further delving into non-native enzymes capable of modifying these products, or other intermediates of cannabinoid synthesis, may well represent non-canonical routes to bioactive compounds, which until now have not been possible to study due to their lack of abundance in the *C. sativa* plant.

Supplementary data

Supplementary data are available at SYN BIO Online.

Material availability statement

Materials used in this study are available on request to the corresponding author.

Funding

The UK Biotechnology and Biological Sciences Research Council (BBSRC). L.K. was funded by PhD studentships supported by the BBSRC.

Acknowledgments

This is a contribution from the EPSRC/BBSRC Future Biomanufacturing Research Hub (EP/S01778X/1) and the BBSRC/EPSRC Synthetic Biology Research Centre SYN BIOCHEM (BB/M017702/1). Molecular graphics and analyses performed with UCSF Chimera in the Supplementary Information document were developed by the Resource for Biocomputing, Visualization, and Informatics at the University of California, San Francisco, with support from the National Institute of Health grant (NIH) P41-GM103311.

Conflict of interest statement. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

1. Taura, F., Sirikantaramas, S., Shoyama, Y., Yoshikai, K., Shoyama, Y. and Morimoto, S. (2007) Cannabidiolic-acid synthase, the chemotype-determining enzyme in the fiber-type *Cannabis sativa*. *FEBS Lett.*, **581**, 2929–2934.

2. van Bakel,H., Stout,J.M., Cote,A.G., Tallon,C.M., Sharpe,A.G., Hughes,T.R. and Page,J.E. (2011) The draft genome and transcriptome of *Cannabis sativa*. *Genome Biol.*, **12**, R102.
3. Grotenhermen,F. and Muller-Vahl,K. (2012) The therapeutic potential of cannabis and cannabinoids. *Dtsch. Ärztebl. Int.*, **109**, 495–501.
4. Pryce,G., Visintin,C., Ramagopalan,S.V., Al-Izki,S., De Faveri,L.E., Nuamah,R.A., Mein,C.A., Montpetit,A., Hardcastle,A.J., Kooij,G. et al. (2014) Control of spasticity in a multiple sclerosis model using central nervous system-excluded CB1 cannabinoid receptor agonists. *FASEB J.*, **28**, 117–130.
5. Giupponi,L., Leoni,V., Pavlovic,R. and Giorgi,A. (2020) Influence of altitude on phytochemical composition of hemp inflorescence: a metabolomic approach. *Molecules*, **25**, 1381.
6. Lopatriello,A., Caprioglio,D., Minassi,A., Schiano Moriello,A., Formisano,C., De Petrocellis,L., Appendino,G. and Tagliatalata-Scafati,O. (2018) Iodine-mediated cyclization of cannabigerol (CBG) expands the cannabinoid biological and chemical space. *Bioorg. Med. Chem.*, **26**, 4532–4536.
7. Lah,T.T., Novak,M., Pena Almidon,M.A., Marinelli,O., Zvar Baskovic,B., Majc,B., Mlinar,M., Bosnjak,R., Breznik,B., Zomer,R. et al. (2021) Cannabigerol is a potential therapeutic agent in a novel combined therapy for glioblastoma. *Cells*, **10**, 340.
8. Mammana,S., Cavalli,E., Gugliandolo,A., Silvestro,S., Pollastro,F., Bramanti,P. and Mazzon,E. (2019) Could the combination of two non-psychotropic cannabinoids counteract neuroinflammation? Effectiveness of cannabidiol associated with cannabigerol. *Medicina*, **55**, 747.
9. Brierley,D.I., Harman,J.R., Giallourou,N., Leishman,E., Roashan,A.E., Mellows,B.A.D., Bradshaw,H.B., Swann,J.R., Patel,K., Whalley,B.J. et al. (2019) Chemotherapy-induced cachexia dysregulates hypothalamic and systemic lipoamines and is attenuated by cannabigerol. *J. Cachexia Sarcopenia Muscle*, **10**, 844–859.
10. Gagne,S.J., Stout,J.M., Liu,E., Boubakir,Z., Clark,S.M. and Page,J.E. (2012) Identification of olivetolic acid cyclase from *Cannabis sativa* reveals a unique catalytic route to plant polyketides. *Proc. Natl. Acad. Sci. U.S.A.*, **109**, 12811–12816.
11. Kearsley,L.J., Prandi,N., Karupiah,V., Yan,C., Leys,D., Toogood,H., Takano,E. and Scrutton,N.S. (2020) Structure of the *Cannabis sativa* olivetol-producing enzyme reveals cyclization plasticity in type III polyketide synthases. *FEBS J.*, **287**, 1511–1524.
12. Luo,X., Reiter,M.A., d'Espaux,L., Wong,J., Denby,C.M., Lechner,A., Zhang,Y., Grzybowski,A.T., Harth,S., Lin,W. et al. (2019) Complete biosynthesis of cannabinoids and their unnatural analogues in yeast. *Nature*, **567**, 123–126.
13. Taura,F., Tanaka,S., Taguchi,C., Fukamizu,T., Tanaka,H., Shoyama,Y. and Morimoto,S. (2009) Characterization of olivetol synthase, a polyketide synthase putatively involved in cannabinoid biosynthetic pathway. *FEBS Lett.*, **583**, 2061–2066.
14. Valliere,M.A., Korman,T.P., Arbing,M.A. and Bowie,J.U. (2020) A bio-inspired cell-free system for cannabinoid production from inexpensive inputs. *Nat. Chem. Biol.*, **16**, 1427–1433.
15. Valliere,M.A., Korman,T.P., Woodall,N.B., Khitrov,G.A., Taylor,R.E., Baker,D. and Bowie,J.U. (2019) A cell-free platform for the prenylation of natural products and application to cannabinoid production. *Nat. Commun.*, **10**, 565.
16. Tello,M., Kuzuyama,T., Heide,L., Noel,J.P. and Richard,S.B. (2008) The ABBA family of aromatic prenyltransferases: broadening natural product diversity. *Cell Mol. Life Sci.*, **65**, 1459–1463.
17. Mansouri,H. and Salari,F. (2014) Influence of mevinolin on chloroplast terpenoids in *Cannabis sativa*. *Physiol. Mol. Biol. Plants*, **20**, 273–277.
18. Chen,R.D., Gao,B.Q., Liu,X., Ruan,F.Y., Zhang,Y., Lou,J.Z., Feng,K.P., Wunsch,C., Li,S.M., Dai,J.G. et al. (2017) Molecular insights into the enzyme promiscuity of an aromatic prenyltransferase. *Nat. Chem. Biol.*, **13**, 226–234.
19. Rinaldi,M.A., Tait,S., Toogood,H.S. and Scrutton,N.S. (2022) Bioproduction of linalool from paper mill waste. *Front. Bioeng. Biotechnol.*, **10**, 892896.
20. Alonso-Gutierrez,J., Chan,R., Batth,T.S., Adams,P.D., Keasling,J.D., Petzold,C.J. and Lee,T.S. (2013) Metabolic engineering of *Escherichia coli* for limonene and perillyl alcohol production. *Metab. Eng.*, **19**, 33–41.
21. Leferink,N.G., Jervis,A.J., Zebec,Z., Toogood,H.S., Hay,S., Takano,E. and Scrutton,N.S. (2016) A 'Plug and Play' platform for the production of diverse monoterpene hydrocarbon scaffolds in *Escherichia coli*. *ChemistrySelect*, **1**, 1893–1896.
22. de Kok,S., Stanton,L.H., Slaby,T., Durot,M., Holmes,V.F., Patel,K.G., Platt,D., Shapland,E.B., Serber,Z., Dean,J. et al. (2014) Rapid and reliable DNA assembly via ligase cycling reaction. *ACS Synth. Biol.*, **3**, 97–106.
23. Carbonell,P., Jervis,A.J., Robinson,C.J., Yan,C., Dunstan,M., Swainston,N., Vinaixa,M., Hollywood,K.A., Currin,A., Rattray,N.J.W. et al. (2018) An automated Design-Build-Test-Learn pipeline for enhanced microbial production of fine chemicals. *Commun. Biol.*, **1**, 66.
24. Benkert,P., Biasini,M. and Schwede,T. (2011) Toward the estimation of the absolute quality of individual protein structure models. *Bioinformatics*, **27**, 343–350.
25. Bertoni,M., Kiefer,F., Biasini,M., Bordoli,L. and Schwede,T. (2017) Modeling protein quaternary structure of homo- and heterooligomers beyond binary interactions by homology. *Sci. Rep.*, **7**, 10480.
26. Bienert,S., Waterhouse,A., de Beer,T.A., Tauriello,G., Studer,G., Bordoli,L. and Schwede,T. (2017) The SWISS-MODEL Repository-new features and functionality. *Nucleic Acids Res.*, **45**, D313–D319.
27. Guex,N., Peitsch,M.C. and Schwede,T. (2009) Automated comparative protein structure modeling with SWISS-MODEL and Swiss-PdbViewer: a historical perspective. *Electrophoresis*, **30**, S162–S173.
28. Studer,G., Rempfer,C., Waterhouse,A.M., Gummienny,R., Haas,J. and Schwede,T. (2020) QMEANDisCo-distance constraints applied on model quality estimation. *Bioinformatics*, **36**, 1765–1771.
29. Waterhouse,A., Bertoni,M., Bienert,S., Studer,G., Tauriello,G., Gummienny,R., Heer,F.T., de Beer,T.A.P., Rempfer,C., Bordoli,L. et al. (2018) SWISS-MODEL: homology modelling of protein structures and complexes. *Nucleic Acids Res.*, **46**, W296–W303.
30. Huang,H., Levin,E.J., Liu,S., Bai,Y., Lockless,S.W., Zhou,M. and Dutzler,R. (2014) Structure of a membrane-embedded prenyltransferase homologous to UBIAD1. *PLoS Biol.*, **12**, e1001911.
31. Briggs,G.E. and Haldane,J.B. (1925) A note on the kinetics of enzyme action. *Biochem. J.*, **19**, 338–339.
32. Kumano,T., Richard,S.B., Noel,J.P., Nishiyama,M. and Kuzuyama,T. (2008) Chemoenzymatic syntheses of prenylated aromatic small molecules using *Streptomyces* prenyltransferases with relaxed substrate specificities. *Bioorg. Med. Chem.*, **16**, 8117–8126.
33. Dong,H., Tao,W., Zhang,Y. and Li,Y. (2012) Development of an anhydrotetracycline-inducible gene expression system for solvent-producing *Clostridium acetobutylicum*: a useful tool for strain engineering. *Metab. Eng.*, **14**, 59–67.
34. Blazeck,J., Garg,R., Reed,B. and Alper,H.S. (2012) Controlling promoter strength and regulation in *Saccharomyces cerevisiae* using synthetic hybrid promoters. *Biotechnol. Bioeng.*, **109**, 2884–2895.
35. Qian,S., Clomburg,J.M. and Gonzalez,R. (2019) Engineering *Escherichia coli* as a platform for the in vivo synthesis of prenylated aromatics. *Biotechnol. Bioeng.*, **116**, 1116–1127.